81228-04-8

Basic information

• Product Name: <<2-(4-fluorophenyl)ethyl>oxy>acetic acid
• Synonyms: <<2-(4-fluorophenyl)ethyl>oxy>acetic acid
• CAS NO: 81228-04-8
• Molecular Weight: 198.194
• Mol File: 81228-04-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: <<2-(4-fluorophenyl)ethyl>oxy>acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: <<2-(4-fluorophenyl)ethyl>oxy>acetic acid(81228-04-8)
• EPA Substance Registry System: <<2-(4-fluorophenyl)ethyl>oxy>acetic acid(81228-04-8)

Safety Data

• Hazardous Substances Data: 81228-04-8(Hazardous Substances Data)

Upstream product

• 7589-27-7 2-(4-Fluorophenyl)ethanol 
• 79-11-8 chloroacetic acid 

Downstream Products

• 81228-18-4 2-<<2-(4-fluorophenyl)ethyl>oxy>ethyl methanesulfonate 
• 81227-92-1 2-fluoro-4-<2-<<2-(4-fluorophenyl)ethyl>oxy>ethoxy>phenol 
• 81228-00-4 3'-fluoro-4'-<2-<<2-(4-fluorophenyl)ethyl>oxy>ethoxy>acetophenone 
• 81227-96-5 1-(benzyloxy)-2-fluoro-4-<2-<<2-(4-fluorophenyl)ethyl>oxy>ethoxy>benzene 
• 86901-92-0 1-tert-Butylamino-3-(4-{2-[2-(4-fluoro-phenyl)-ethoxy]-ethoxy}-phenoxy)-propan-2-ol 
• 81228-35-5 Flusoxolol 
• 86901-90-8 (R)-1-(4-{2-[2-(4-Fluoro-phenyl)-ethoxy]-ethoxy}-phenoxy)-3-isopropylamino-propan-2-ol 
• 84057-96-5 flusoxolol 
• 81228-31-1 1-[2-fluoro-4-[2-(4-fluorophenethyloxy)ethoxy]phenoxy]-3-isopropylamino-2-propanol 
• 1354966-79-2 C₂₈H₃₄FN₃O₆ 
• 1354968-45-8 2-((4-(2-(4-fluorophenethyloxy)ethyloxy)phenoxy)methyl)oxirane 
• 1354968-44-7 4-(2-(4-fluorophenethyloxy)ethyloxy)phenol 
• 1354968-40-3 1-(2-(4-fluorophenethyloxy)ethyloxy)-4-(benzyloxy)benzene 
• 81228-11-7 4-Fluoro-1-[2-[2-hydroxyethoxy]ethyl]benzene 

Relevant articles and documents

Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists

β-Adrenoceptor antagonists boast a 50-year use for symptomatic control in numerous cardiovascular diseases. One might expect highly selective antagonists are available for the human β-adrenoceptor subtype involved in these diseases, yet few truly β1-selective molecules exist. To address this clinical need, we re-evaluated LK 204-545 (1),(1) a selective β1-adrenoceptor antagonist, and discovered it possessed significant partial agonism. Removal of 1's aromatic nitrile afforded 19, a ligand with similar β1-adrenoceptor selectivity and partial agonism (log KD of -7.75 and -5.15 as an antagonist of functional β1- and β2-mediated responses, respectively, and 34% of the maximal response of isoprenaline (β1)). In vitro β-adrenoceptor selectivity and partial agonism of 19 were mirrored in vivo. We designed analogues of 19 to improve affinity, selectivity, and partial agonism. Although partial agonism could not be fully attenuated, SAR suggests that an extended alkoxyalkoxy side chain, alongside substituents at the meta- or para-positions of the phenylurea, increases ligand affinity and β1-selectivity.

Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: Optimization of in vitro activity

Pyrido pyrimidinones are selective agonists of the human high affinity niacin receptor GPR109A (HM74A). They show no activity on the highly homologous low affinity receptor GPR109B (HM74). Starting from a high throughput screening hit the in vitro activity of the pyrido pyrimidinones was significantly improved providing lead compounds suitable for further optimization.

SUBSTITUTED PHENOXY-AMINOPROPANOLS

Substituted phenoxy-aminopropanols of the formula STR1 wherein R is a branched-chain alkyl of 3 or 4 carbon atoms, R 1 is hydrogen, halogen or lower alkyl and R 2 and R 3, independently, are hydrogen, halogen, lower alkyl, lower alkoxy or lower alkylthio, and pharmaceutically acceptable acid addition salts thereof, are described. A process for their preparation, as well as pharmaceutical preparations containing them are also described. The compounds of formula I and their salts possess cardioselective β-adrenergic blocking activity and antihypertensive activity.